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Introduction
Diagnostic tests are an essential part of modern 
medicine, including respiratory diseases. The 
ultimate goal of diagnosis and monitoring is to 
optimize the outcome or prognosis for the patient 
by giving the clinician directions for a clinical 
management strategy. Even though physiological 
and cell-based procedures, such as spirometry 
and induced sputum are often routinely available, 
molecular diagnostics are not widely applicable at 
point of care.
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Abstract
New ‘omics’-technologies have the potential to better define airway disease in terms of 
pathophysiological and clinical phenotyping. The integration of electronic nose (eNose) technology 
with existing diagnostic tests, such as routine spirometry, can bring this technology to ‘point-of-care’.
We aimed to determine and optimize the technical performance and diagnostic accuracy of 
exhaled breath analysis linked to routine spirometry.
Exhaled breath was collected in triplicate in healthy subjects by an eNose (SpiroNose) based on 
five identical metal oxide semiconductor sensor arrays (three arrays monitoring exhaled breath 
and two reference arrays monitoring ambient air) at the rear end of a pneumotachograph. First, 
the influence of flow, volume, humidity, temperature, environment, etc, was assessed. Secondly, a 
two-centre case-control study was performed using diagnostic and monitoring visits in day-to-day 
clinical care in patients with a (differential) diagnosis of asthma, chronic obstructive pulmonary 
disease (COPD) or lung cancer. Breathprint analysis involved signal processing, environment 
correction based on alveolar gradients and statistics based on principal component (PC) analysis, 
followed by discriminant analysis (Matlab2014/SPSS20).
Expiratory flow showed a significant linear correlation with raw sensor deflections (R2  =  0.84) 
in 60 healthy subjects (age 43  ±  11 years). No correlation was found between sensor readings and 
exhaled volume, humidity and temperature. Exhaled data after environment correction were highly 
reproducible for each sensor array (Cohen’s Kappa 0.81–0.94).
Thirty-seven asthmatics (41  ±  14.2 years), 31 COPD patients (66  ±  8.4 years), 31 lung cancer 
patients (63  ±  10.8 years) and 45 healthy controls (41  ±  12.5 years) entered the cross-sectional 
study. SpiroNose could adequately distinguish between controls, asthma, COPD and lung cancer 
patients with cross-validation values ranging between 78–88%.
We have developed a standardized way to integrate eNose technology with spirometry. Signal 
processing techniques and environmental background correction ensured that the multiple 
sensor arrays within the SpiroNose provided repeatable and interchangeable results. SpiroNose 
discriminated controls and patients with asthma, COPD and lung cancer with promising accuracy, 
paving the route towards point-of-care exhaled breath diagnostics.
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Exhaled breath contains thousands of volatile 
organic components (VOCs) that originate from both 
systemic and local metabolic processes, which can be 
associated with normal physiology or pathophysiologi-
cal inflammatory or oxidative activity [1, 2]. There are 
several technologies that can be applied to exhaled breath 
analysis, the standard being represented by identification 
of individual molecular compounds by analytical chem-
istry techniques, such as gas chromatography with mass 
spectrometry (GCMS) [1]. This is mandatory for patho-
physiological research. Additionally, electronic noses 
(eNoses) are used with the objective of recognition of gas 
mixtures, by using a variety of cross-reactive sensors that 
capture the spectrum of VOCs in exhaled air without the 
identification of the individual components [3].
Studies conducted thus far in the research field of 
respiratory diseases suggest that eNose technology has 
potential to proceed towards a diagnostic and monitoring 
tool [4]. It has already been shown that by using eNoses 
lung cancer, inflammatory diseases such as asthma and 
chronic obstructive pulmonary disease (COPD), and 
infectious diseases can be distinguished with accuracies 
that are approaching traditional diagnostic tests [5–13].
Recently, combined technical and medical efforts 
have resulted in the compilation of the ‘SpiroNose’ 
(AMC, Amsterdam; Comon-Invent BV, Delft, The 
Netherlands), an online and real-time, database driven 
eNose designed for medical purposes, which can be 
used in combination with routine lung function test-
ing. Online real-time analysis offers several advantages 
as compared with indirect sampling, notably by retriev-
ing immediate results, and avoiding laborious collec-
tion and storage steps. This eliminates a major source 
of experimental errors in exhaled breath analysis, par-
ticularly those related to the loss of compounds (e.g. 
compounds that change rapidly as a function of exter-
nal influence or unstable compounds that decompose 
before being analyzed [14, 15]). To control and mini-
mize variables known to influence exhaled breath anal-
ysis, we integrated eNose technology with spirometry. 
Integration of eNose with existing diagnostic tests, such 
as routine spirometry, brings this technology to ‘point-
of-care’ and links it to regular clinical procedures.
We hypothesized that the SpiroNose is an accurate 
and valid technology to measure exhaled breath in a 
clinical setting. This study aimed to technically and 
medically validate the SpiroNose in order to proceed 
towards its clinical application. To that end we per-
formed an extensive technical validation, including the 
development of signal-processing and data-analysis 
techniques and validated the diagnostic accuracy in a 
daily practice setting.
Methods
Subjects
Technical validation
To validate the technical performance of the SpiroNose 
60 healthy adult subjects, willing to participate in this 
validation study, were included. The healthy controls 
were recruited by advertisement at the university 
campus of Amsterdam.
Clinical study
Adult subjects (n  =  144) were included in this study. 
Subjects were divided into four groups according 
to current diagnosis: (1) patients with mild to severe 
asthma; (2) moderate to severe COPD; (3) lung cancer; 
and (4) healthy controls. Patients were recruited 
among those visiting the lung function departments 
at the Academic Medical Centre (AMC) Amsterdam 
and Medical Spectrum Twente (MST) Enschede, 
whereas controls were recruited by advertisement at 
the university campus of both study sites.
The asthma group consisted of 37 patients with 
episodic chest symptoms, smoking history  <10 pack 
years, a documented reversibility in FEV1 of  ⩾12% 
predicted or 200 ml after 400 μg salbutamol or airway 
hyperresponsiveness (PC20 methacholine or hista-
mine  <8 mg ml−1) [16]. The COPD group consisted 
of 31 patients with a smoking history  ⩾15 pack years, 
symptoms of dyspnea, chronic cough and/or sputum 
production, a postbronchodilator FEV1  <80% of pre-
dicted and FEV1/FVC ratio  <0.70 (GOLD stage II–IV 
according to GOLD guidelines [17]). 31 Lung cancer 
patients were recruited with an established medical 
diagnosis of lung cancer based on current guidelines 
[18, 19]. The control group included 45 subjects with 
a negative history for chest symptoms, a postbroncho-
dilator FEV1  >80% predicted and FEV1/FVC  >0.70. 
Subjects were excluded in case of insulin-dependent 
diabetes, respiratory infection and pulmonary disease 
other than asthma, COPD and lung cancer.
The ethics board of AMC Amsterdam (dd. 07-05-
2014) and MST Enschede (dd. 05-06-2014) concluded 
in writing that Dutch legislation on human participa-
tion in research was not considered to be applicable 
given the non-invasive nature of the study and of its 
integration into routine diagnostic lung function.
Design
First, the influence of integration of eNose with the 
pneumotachograph was assessed. Additionally, we 
assessed the robustness of the technique against 
variables potentially influencing SpiroNose 
measurements such as, expiratory airflow, exhaled 
breath volume, humidity, temperature, ambient 
substances and the use of a bacterial filter. Finally, 
signal-processing techniques and two essential eNose 
features, sensor stability and reproducibility, were 
addressed.
Second, the clinical validation had a two-centre 
cross-sectional case-control design merely using the 
diagnostic and monitoring visits of day-to-day care 
in clinical practice. After screening for in- and exclu-
sion criteria, the measurements were performed as 
part of pulmonary function testing. Patients were not 
instructed to refrain from eating, drinking, smoking 
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or discontinue any medication to increase applicabil-
ity in clinical practice. Patients were requested to rinse 
their mouth thoroughly three times with water. Sub-
sequently, exhaled breath analysis was performed in 
duplicate with a 2 min interval.
Measurements
Exhaled breath analysis was performed using the 
SpiroNose, an eNose designed for medical purposes that 
can be used as add-on to routine lung function testing. 
The SpiroNose consists of five separate sensor arrays, 
each comprising four metal oxide semiconductor 
(MOS) sensors (Figaro, Japan). The choice of Figaro-
type MOS sensors was based on their good long-term 
performance and stability [20]. Two of the sensor arrays 
were used as reference arrays to detect the ambient 
VOCs and three sensor arrays were used to monitor 
the VOCs in exhaled breath (figure 1). All sensor arrays 
are identical and consist of four different MOS sensors 
with operating temperatures ranging between  −40 °C 
and  +70 °C. Using thick film techniques, the sensor 
material is printed on electrodes onto an alumina 
substrate. The four MOS sensors all used tin dioxide 
(SnO2) as the main sensing material of the sensor 
element. The complete measurement setup used in this 
study consists of a soft bite mouthpiece, nose clamp and 
viral/bacterial filter (Lemon Medical GmbH) attached 
to a Masterscreen™ PFT system (Masterscreen, Jaeger, 
Care Fusion) and the SpiroNose (figure 1).
Technical performance 
To verify that the addition of the SpiroNose to the 
pneumotachograph did not influence spirometry 
results healthy controls performed three reproducible 
FVC maneuvers for three different device setups; (1) 
regular pneumotach flow and volume calibration by 
a 3 L calibration syringe (2) regular calibration before 
the addition of the SpiroNose and (3) calibration after 
adding the SpiroNose to the setup. The three device 
setups were used in random order to exclude the 
influence of fatigue and habituation to the exercise.
By using available and specialized software (J-scope, 
Jaeger) included on the PFT system, flow, volume, time 
and moment of in/expirations during measurements 
were determined. The humidity and temperature were 
registered before every measurement by the Master-
screen™ PFT system with the additional SentrySuite 
software.
To gain insight in the ambient gases/VOCs that 
are present during exhaled breath measurements, the 
ambient VOCs were detected by the reference sensor 
arrays of the SpiroNose.
Furthermore, the influence of a bacterial filter was 
addressed by comparing SpiroNose sensor deflections 
with and without a bacterial filter in both a patient and 
control group (10 asthma patients (age 30  ±  6.9 years, 
FEV1 93  ±  11.2% predicted) versus 10 healthy controls 
(age 28  ±  7.4, FEV1 105  ±  7.2)). Bacterial filters placed 
after the mouthpiece represent a routine procedure for 
hygiene purposes. The SpiroNose measurements were 
performed in duplicate with a 2 min time interval. After 
two weeks, the healthy controls and asthma patients 
performed the same measurements to determine both 
within-day and between-day repeatability.
SpiroNose sensor stability was verified using a 
test gas (Lindegas, for the measurement of pulmo-
nary diffusion capacity) as quality control (QC) gas 
before every session. This QC gas is a standard mix-
ture of acetylene (0.300  ±  0.015%), carbon monoxide 
(0.300  ±  0.015%), methane (0.300  ±  0.015%), oxy-
gen (20.7  ±  1.0%) and nitrogen used as a balance gas. 
To verify sensor stability over the course of this study, 
each morning before exhaled breath measurements the 
demand valve was placed at the rear end of the Spiro-
Nose. Subsequently, the gas mixture was flushed for 
5 s with a mean flow of 3 L s−1 through the SpiroNose, 
which was measured with the pneumotachograph. In 
addition, we assessed the sensor variability relative to 
Figure 1. (Left) Patient breathing through the SpiroNose measurement setup, including: (1) a viral and bacterial filter with a soft 
bite mouthpiece and nose clamp (Lemon Medical GmbH); (2) the Masterscreen PFT system (Masterscreen, Jaeger, Carefusion); and 
(3) the SpiroNose (AMC Amsterdam, Comon Invent Delft). (Right) The SpiroNose composed of five sensor arrays, each comprising 
four MOS sensors. (Red arrows) three arrays of MOS sensors placed inside the tube for exhaled breath analysis. (Red circles) two 
arrays of MOS sensors placed at the outside of the tube, used for environment correction.
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the effect size observed when discriminating subject 
groups to obtain the signal-to-noise ratio.
Finally, the exhaled breath results of the 60 healthy 
controls, obtained in triplicate by the three identical sen-
sor arrays that monitor VOCs in exhaled breath, were used 
to determine reproducibility of the four MOS sensors. We 
compared the unprocessed (figure 3(A)) and processed 
(figure 3(B)) sensor deflections of the three identical sen-
sor arrays for sensor-to-sensor reproducibility.
Clinical validation 
Exhaled breath measurements were performed 
right before regular spirometry. All patients were 
instructed to start the measurement by performing 10 
tidal breaths. After a single deep inspiratory capacity 
maneuver and a 5 s breath hold the patient exhaled, 
with an expiratory flow  <0.4 L s−1, a vital capacity 
volume into the measurement setup. Exhaled breath 
was directly sampled in triplicate by the SpiroNose, 
which is connected to a GSM-module that ensures that 
the obtained data (changes in electrical voltage) are 
real-time transmitted and stored at the online server 
of Comon Invent BV, Delft, without the addition of 
patient-related data. Here, data could be downloaded, 
whereupon it was further processed and analyzed using 
offline pattern-recognition software.
Data-analysis
Clinical validation 
The primary analysis of the clinical study was done 
by comparing the exhaled breathprints between 
patients with asthma, COPD, lung cancer and healthy 
controls. Secondarily, the exhaled breathprints 
between asthma patients measured at different 
study sites (AMC versus MST) were compared to 
investigate whether the used data sampling and 
analysis techniques are appropriate for multi-center 
purposes. Offline analysis of raw sensor data was 
performed using Matlab (MathWorks, 2014) and 
SPSS (version 20). First, data were pre-processed and 
corrected for ambient VOCs. Subsequently, the data 
was normalized and reduced by principal component 
analysis (PCA) after which cases were classified into a 
categorical division.
Environment correction 
The environment correction was based on the 
calculation of alveolar gradients [21–23]. Alveolar 
gradients were obtained by subtracting inspiratory 
(reference signal) from expiratory VOC concentrations 
(patient signal) [22, 23]. Reference sensor signals were 
filtered using a low-pass Butterworth filter to extract 
the overall shape of the signal, followed by linear trend 
removal based on a least squares fit. Subsequently, both 
reference signals were averaged. Cross-correlation 
was used to obtain the highest correlation between 
reference and patient signal, as both showed a similar 
but delayed pattern. Finally, the patient sensor signals 
were filtered using a low-pass Butterworth filter before 
subtracting the processed and averaged reference 
signal. Following this environment correction, linear 
trends and offsets were removed from the patient 
signals. The three processed and corrected patient 
signals were not averaged.
Peak detection 
The exhaled breath analysis was performed in 
duplicate. Peak values of the sensor signals were 
detected using an automatic peak detection algorithm 
implemented in Matlab for both measurements. This 
algorithm automatically finds the local maxima in 
a vector (patient signal). In order to create exhaled 
breathprints, the highest sensor peak of both 
measurements for each sensor signal was selected and 
normalized with respect to the most sensitive sensor 
(range: 1–30 ppm) with the highest corrected sensor 
values, sensor 4. The study focused on sensor-to-sensor 
ratios rather than absolute sensor values, to minimize 
inter-array differences.
Statistical analysis 
Pre-processed exhaled breath data were restructured 
by PCA from the original 12 sensors monitoring 
exhaled breath (three sensor arrays of four MOS 
sensors) to four principal components according the 
Kaiser criterion [24]. The obtained PCA factors were 
used to perform a univariate ANOVA analysis to select 
the principal components that were discriminative 
between groups. Breathprints were internally validated 
by multiple iterations of bootstrap. Furthermore, 
PCA was used as an exploratory analysis plotted in 
3D graphs to visualize between-group separations. 
Subsequently, linear canonical discriminant analysis 
was performed to plot cases on a linear classifier. Based 
on the differentiating PCA factors, a discriminant 
function was calculated that best distinguished between 
categories. The accuracy of this model was defined as 
the percentage of correctly classified patients, cases 
and controls combined. Cross-validation using the 
leave-one-out method was used to calculate the cross-
validated accuracy value (CVV, %). The discriminant 
Table 1.  Subject characteristics and pulmonary function of 
healthy controls included for the technical validation of the 
SpiroNose.
Controls (n  =  60)
Age, years 42.7 (11.1)
Gender (M/F) 23/37
BMI 24.0 (4.3)
FEV1 postbronchodilator (%pred) 101.9(7.5)
FEV1/FVC 0.8(0.07)
Current / ex- / never-smoker 4/29/27
Pack years 5.5 (9.4)
ICS-use (n) 0
Note: values are expressed as mean (SD). BMI—body mass 
index; FEV1—forced expired volume in 1 s; FVC—forced 
vital capacity; ICS—inhaled corticosteroids.
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functions were used to construct receiver operator 
characteristic (ROC) curve. The area under the curve 
(AUC) and single spot test sensitivity and specificity 
were determined. Finally, reproducibility was assessed 
by comparison of the three identical sensor arrays 
monitoring patient’s exhaled breath using Cohen’s 
kappa analysis.
Results
Subject characteristics of healthy controls included 
for technical validation of the SpiroNose are presented 
in table 1. The subject characteristics and pulmonary 
function of patient groups included for clinical 
validation of the SpiroNose are described in table 2. 
Healthy controls and patients with asthma were 
significantly younger than patients with COPD and 
lung cancer (p  <  0.01). There were no significant 
differences in age between healthy controls and asthma 
patients and between patients with COPD and lung 
cancer. The postbronchodilator FEV1 (% predicted) in 
asthma patients was significantly lower than in healthy 
controls (p  <  0.01), but significantly higher than in 
COPD (p  <  0.01) and lung cancer patients (p  <  0.01). 
Furthermore, nine lung cancer patients were also 
diagnosed with COPD.
Technical performance
A strong linear correlation (R2  =  0.84) was found for 
sensor 1 between expiratory flow and absolute sensor 
deflections (figure 2). Between 0.19 and 0.38 L s−1 
absolute sensor values were not significantly influenced 
by the expiratory flow rate (p  >  0.5). Similar results 
were found for sensor 2–4. In addition, a significant 
linear correlation (R2  =  0.75) was found between 
sensor-to-sensor ratio (S1/S4) and the expiratory 
flow. The sensor ratios S2/S4 and S3/S4 again showed 
comparable results.
No correlation was observed between the sensor 
readings and the exhaled volume for sensor 1 (figure 2). 
Comparable results were found for sensors 2–4.
There were no significant differences in spirometry 
results between the three device setups related to adding 
the SpiroNose to the pneumotachograph (p  >  0.5). Fur-
thermore, no significant correlation was found between 
sensor-to-sensor ratios and temperature or humidity 
(p  >  0.5) (figure S1 of the supplementary data).
Distinct breathprints were found for a subgroup 
of healthy controls and patients with asthma between 
using (p  <  0.01, CVV 83%) and not using (p  <  0.01, 
CVV 78%) a bacterial filter. In addition, the Spiro Nose 
established intraclass correlation coefficient (ICC) val-
ues ranging between 0.81–0.86 for within-day repeat-
ability and 0.69–0.80 for between-day repeatability 
(supplementary data; 1.3 and 1.4).
The effect size obtained when discriminating the 
various subject groups was 5.2 till 7.4-fold higher than 
the normal sensor variability, indicating a good signal-
to-noise ratio. More detailed information about these 
results can be found in the supplementary information.
The results obtained by the specified data analy-
sis techniques used to create breathprints were com-
pared to the unprocessed sensor data analysis for 60 
healthy controls (figure 3). Data of four MOS sensors 
are presented for sensor array 1, 2 and 3. Analysing the 
unprocessed data showed significant differences in 
breathprints between the three identical sensor arrays 
for sensor 1 (p  <  0.001) and sensor 3 (p  <  0.05), while 
each sensor array monitored the same exhaled breath 
(figure 3(A)). When data were processed and corrected 
for ambient VOCs, breathprints did not show sig-
nificant differences for sensor 1–4 (figure 3(B)) and a 
Table 2. Subject characteristics and pulmonary function in patients with asthma, COPD, lung cancer and healthy controls.
Controls Asthma COPD Lung cancer
No. 45 37 31 31
Age, years 41.5(12.5) 41.4(14.2) 66.6(8.4) 62.5(10.8)
Gender (M/F) 19/26 15/22 15/16 18/13
BMI 24.7(4.2) 26.1(5.4) 27.9(5.5) 27.3(4.8)
FEV1 postbronchodilator (%pred) 103.9(8.5) 85.3(18.9) 49.9(20.3) 71.4(19.1)
FEV1/FVC 0.79 (0.05) 0.67(0.08) 0.41(0.11) 0.69(0.15)
GOLD-stage (II/III/IV) NA NA 9/15/7 2/6/1
GINA-classification
NA 10/18/9 NA NA Mild / moderate / severe
Lung cancer histologic subtype
NA NA NA 12/19 SCLC /NSCLC
Lung cancer stage II/III/IV NA NA NA 2/8/21
Current / ex- / never-smoker 1/21/23 0/8/29 8/23/0 10/18/3
Pack years 5.5 (9.4) 1.9(6.4) 36.1(12.7) 31.9(16.6)
ICS-use (n) 0 35 26 6
Note: values are expressed as mean (SD). NA—not applicable; BMI—body mass index; FEV1—forced expired volume 
in 1 s; FVC—forced vital capacity; SCLC—small cell lung cancer; NSCLC—non-small cell lung cancer; ICS—inhaled 
 corticosteroids.
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Cohen’s kappa ranging from 0.81 to 0.94 was achieved, 
thereby showing high between-sensor reproducibility.
Clinical validation
Principal component analysis with ANOVA showed 
that exhaled breath data from patients with asthma 
and COPD could be well distinguished (p  =  0.001). 
Subsequent discriminant analysis showed a cross-
validated accuracy value of 81% (figure 4). The 
ROC-AUC  ±95% confidence interval after internal 
cross-validation reached 0.81  ±  0.09. Breathprints 
of COPD patients could also be discriminated from 
those of lung cancer patients (p  =  0.002; CVV: 80%), 
with an ROC-AUC of 0.88  ±  0.11 (figures 4 and 5). 
When excluding those lung cancer patients with co-
morbid COPD from the latter analysis, the COPD 
and lung cancer patients could still be distinguished 
(p  <  0.001) with a cross-validated accuracy of 87% and 
a ROC-AUC of 0.91  ±  0.12. For completeness, exhaled 
breath data from lung cancer and asthma patients 
were discriminated (p  =  0.045) with a cross validated 
accuracy of 68%. The ROC-AUC reached 0.71  ±  0.09.
Breathprints of asthma patients were distinguished 
from those of healthy controls (p  <  0.001) with a 
cross-validated accuracy value of 87% and an ROC-
AUC of 0.94  ±  0.15. Exhaled breath results of COPD 
Figure 3. (A) Normalized but unprocessed sensor values (sensor 1–4) given for sensor array 1, 2 and 3 (monitoring the exhaled 
VOCs). (B) Normalized sensor values (sensor 1–4) after signal pre-processing and correction for ambient VOCs, for sensor array 1, 2 
and 3. Sensor values are normalized with respect to sensor 4.
Figure 2. (Left) Linear relation between expiratory flow and absolute sensor values for sensor 1. (Right) The relation between 
expiratory volume and absolute sensor values for sensor 1.
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patients and controls were discriminated (p  =  0.001) 
with a cross validated accuracy of 78%. The ROC-
AUC reached 0.80  ±  0.10. Furthermore, breathprints 
from patients with lung cancer and healthy controls 
were very well distinguished (p  <  0.001) and a cross-
validated accuracy value of 88% was achieved with an 
ROC-AUC of 0.95  ±  0.11 (figure 4).
Finally, no significant difference was found between 
exhaled breathprints obtained from asthma patients 
measured at different study sites (p  =  0.892) (figure 6).
Discussion
The present study shows that integration of an eNose 
with spirometry is feasible without influencing lung 
function results (p  >  0.5). Exhaled breath analysis 
with this technique, by SpiroNose, provided adequate 
discrimination between healthy controls, patients 
with asthma, COPD and lung cancer. Repeated 
measurements showed adequate reproducibility and 
confirmed this distinction. This indicates that the 
SpiroNose and the associated data analysis techniques 
are suited for exhaled breath profiling in a point-of-
care setting. Our findings warrant further validation 
of the SpiroNose regarding its ability to correctly 
identify patients with various (respiratory) diseases in 
independent, external populations.
To our knowledge this is the first study that aimed 
to integrate eNose technology with spirometry to 
conduct exhaled breath measurements in daily clini-
cal practice, without additional restrictions in eating, 
drinking, smoking and medication. We were not able 
to integrate the two completely, since the required flow 
for exhaled breath analysis is not the same as obtained 
during spirometry. Our findings are showing the need 
for a desired flow range for SpiroNose assessment that 
Figure 4. Cross-validation values (%) for the discrimination between healthy controls and patients with asthma, COPD and lung 
cancer.
Figure 5. (Left) 3D PCA plot showing the discrimination of breathprints between patients with COPD and lung cancer along 
discriminative principal components (CVV:80%, p  =  0.002). (Right) ROC-curve with line of identity of the breathprint 
discriminant function (representing PC 1, 2 and 3), predictive for the differential diagnosis of asthma and COPD (AUC 0.88).
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can easily be monitored by spirometry, thereby ensur-
ing quality control of exhaled breath analysis. In doing 
so, patients can conveniently perform exhaled breath 
measurements before spirometry within less than 
2 min, making this technology suitable for point of care.
Our work extends the results of many research 
groups who performed exhaled breath analyses in 
patients with asthma [8, 10, 12, 25], COPD [7, 9, 13, 25] 
and lung cancer [5–7, 11] and obtained similar cross-
validated accuracies. Nevertheless, complete separation 
of these disease could not be accomplished. First, COPD 
is also a frequent comorbidity in lung cancer. Therefore, 
it may not be surprising that exhaled breath profiles by 
electronic noses have shown definite overlap between 
lung cancer and COPD [7]. When we excluded lung 
cancer patients with co-morbid COPD from the clini-
cal analysis between COPD and lung cancer patients 
the discrimination became even better. This may sug-
gest that the patients with a double diagnosis were cor-
rectly allocated in the overlap area. Second, the obtained 
CVV for the distinction between asthma and lung can-
cer patients was surprisingly low. This outcome has no 
clinical implication as asthma versus lung cancer is not 
a differential diagnosis, but the result requires further 
studies using GC-MS on the proliferative, oxidative and 
inflammatory mechanisms involved in both diseases.
In this study, we performed both a clinical and 
technical validation of the newly developed  SpiroNose, 
which exhibited strengths and limitations. For the 
clinical validation we included three relevant groups of 
patients as commonly seen in daily practice and one 
asymptomatic control group. International guide-
lines for evaluating diagnostic accuracy of a novel test, 
recommend evaluation of the discriminative ability 
between predefined, gold standard diseased and non-
diseased subjects as the initial step [26]. Although 
our subjects were well characterized, there were some 
inevitable differences between the groups. First, healthy 
controls and patients with asthma were significantly 
younger than COPD and lung cancer patients. These 
differences potentially introduced an age-bias in the 
between-group separations, although Dragonieri 
et al showed that VOC profiles in exhaled breath from 
young (26  ±  6 years) and older (57  ±  7 years) healthy 
controls could not be separated [8]. Second, the dif-
ference in medication use (ICS) between COPD and 
lung cancer patients could have influenced the exhaled 
VOC-profiles. We have previously shown that the dif-
ference in VOC-profiles between asthma and COPD 
patients (CVV: 97%, p  <  0.0001) remained signifi-
cant after removal of the difference in ICS-use (CVV: 
95%, p  <  0.0001), by restricting both groups to those 
patients using ICS [25]. Although these results were 
obtained with a different eNose, we believe that the 
differences in exhaled breathprints between patients 
with asthma, COPD and lung cancer, found with the 
 SpiroNose, are disease related.
The SpiroNose consists of five identical sensor 
arrays (sensor array 1–3 monitoring exhaled breath 
and sensor arrays 4–5 are reference arrays) containing 
four different MOS sensors. Romain et al tested a large 
number of sensors with different sensor technologies 
and showed that metal oxide-based gas sensors (Figaro, 
JP) exhibited the best long-term stability [20]. When 
developing the SpiroNose we reasoned that correction 
for ambient VOCs based on two reference sensor arrays 
would be required for optimal performance. Because of 
the large similarity of responses between sensor arrays 
in the present study, in retrospect this strategy might 
have been overly cautious.
Reproducibility data for sensor arrays 1, 2 and 3 
showed significant improvement after signal processing 
and correction for ambient VOCs, with Cohen’s kappa 
results ranging from 0.81 to 0.94. This suggests that 
the location of the sensors in the tubing does not affect 
exhaled breath results. Furthermore, this signal pro-
cessing demonstrates that the data analysis techniques 
used are appropriate for exhaled breath sampling by 
SpiroNose. Interestingly, with this small number of 
MOS sensors comparable accuracy levels were achieved 
as previously described in literature with other eNoses, 
including arrays using far more sensors [4]. Apparently, 
increasing the sensor array number does not necessarily 
improve eNose classification performance as that could 
amplify the noise and/or generate redundancy of infor-
mation [3, 27].
Regarding the technical validation we found a linear 
correlation between exhaled breath sensor deflections 
and the expiratory flow. Dragonieri et al [8] studied the 
possible effects of expiratory flow during vital capac-
ity in healthy non-smokers by using 100–200 ml s−1 
and 300–500 ml s−1 in a random order with a 30 min 
interval. Within the 100–200 ml s−1 flow range; expira-
tory flow had a limited effect on eNose measurements. 
In addition, Pedroletti et al [28] studied the NO levels 
Figure 6. 2D PCA plot showing no significant discrimination 
of breathprints from asthma patients measured at the 
Academic Medical Center (AMC), Amsterdam and Medical 
Spectrum Twente (MST), Enschede.
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at six different exhalation flow rates in 15 asthmatic 
schoolchildren with elevated NO levels and 15 age-
matched controls. They found that a targeted flow rate 
of approximately 50 mL s−1 seems to be most appropri-
ate for single-breath measurements when considering 
discriminatory power, reproducibility and patient com-
fort. Taken together, our data suggest that expiratory 
flow rates between 0.19 and 0.38 L s−1 are suitable for 
SpiroNose measurements. Nevertheless, further stud-
ies are required to address the effect of expiratory flow 
on eNose measurements, particularly after a period of 
normal breathing (as opposed to single-breath sam-
pling), and in patients with various respiratory diseases 
[29]. When using the SpiroNose setup connected to 
spirometry, it is not possible to regulate expiratory flow 
by means of a resistor. The expiratory flow can only be 
influenced by instructing the patient, which if needed 
can be achieved by e.g. visual feedback from pneumot-
achograph measurements. We asked patients to exhale 
the expiratory vital capacity very slowly, preferably 
with a flow between 0.19 and 0.38 L s−1, at which the 
MOS sensors likely become saturated thereby limiting 
the effect of expiratory flow at this flow range during 
SpiroNose measurements in practice (figure 2).
Due to technical feasibilities sensor stability was 
validated by flushing pulmonary diffusion test gas with 
3 L s−1 through the SpiroNose. For this we conveniently 
used the demand valve, which is part of the Master-
screen PFT system, but the latter did not allow us to 
manually flush the test gas at a lower flow rate. Even 
though it would have been most optimal to determine 
sensor stability with a flow  <0.4 L s−1, we believe sensor 
stability results regarding the absence of linear trends 
and assessment of the sensor variability relative to the 
effect size are representative for these MOS sensors. For 
the exhaled breath measurements we asked patients to 
exhale vital capacity very slowly, preferably with a flow 
between 0.19 and 0.38 L s−1. Here, sensor readings sug-
gested that the MOS sensors became saturated. There-
fore, we expect sensor stability to increase when meas-
ured at a flow rate  <0.4 L s−1 instead of 3 L s−1 since the 
influence of flow will be minimal.
In the present study we decided to sample an inte-
grative exhaled air sample, as it is yet unknown whether 
the discriminative VOC signals arise from the airways 
and/or the alveoli [12]. In addition, even alveolar sam-
ples are trafficking through the conducting airways and 
oropharynx, which may complicate interpretations of 
separated airways and alveolar samples. The SpiroNose 
uses real-time analysis in order to measure the integra-
tive exhaled air sample, implicating that dead space 
air samples can be separated in time compared to the 
alveolar air samples.
The applied real-time approach of breath sampling 
has the advantage of increasing breath VOC concentra-
tions and stability of the total exhaled breath sample 
[29]. Direct breath sampling is a very appealing option, 
since it makes the widely used collecting bags unneces-
sary. Tedlar bags, which are recommended by the US 
Environmental Protection Agency [30] for ambient 
gas sampling, are widely used for breath sampling in 
patients with respiratory disease. However, if bags are 
exposed to direct sunlight and over time Tedlar bags 
can release hydrocarbons N,N-dimethylacetamide and 
phenol [31]. Furthermore, there may be considerable 
carryover effects from previous measurement. There-
fore, SpiroNose real-time sampling and analysis may 
not only be practical for clinical usage, but may also 
merit unaffected VOC assessment.
In conclusion, we have shown that eNose analysis 
of exhaled biomarkers can be integrated with spirom-
etry. This provides a simple approach to exhaled 
breath analysis we have shown to be able to discrimi-
nate between patients with asthma, COPD and lung 
cancer. Furthermore, we have shown adequate repro-
ducibility and transferability of algorithms between 
devices. The latter will allow exchange of results 
between different labs and locations, which is a pre-
requisite for clinical implementation [32]. Therefore, 
the SpiroNose may strongly contribute to bringing 
the promise of exhaled breath diagnostics to clinical 
practice, particularly when linked to an online data-
base (www.breathcloud.org).
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